Praxis Precision Medicines (PRAX.US) Financial Statements - Balance Sheet/Income Statement/Cash Flow

Quote List Quote List

Event Tracking

Dec5

LifeSci Capital analyst reiterates buy rating and raises target price for Praxis Precision stock

12:46

Dec4

Praxis Plans to Submit New Drug Application for Essential Tremor Treatment in Q1 2026

21:21

Praxis Precision Medicines Stopped Relutrigine's EMBOLD Study Early

21:11

Nov24

H.C. Wainwright Analyst Reiterates Buy Rating for Praxis Precision Medicines

22:27

Praxis Precision to Present Positive Study Results for Drug Treating Refractory Epilepsy

21:01

Nov22

Praxis Precision Medicines Inc executive Lauren Mastrocola sold 13,600 shares

02:46

Schedules & Filings

Schedules

Filings

Nov5

Earning Release(EST)

FY2025 Q3 Earning Release (USD) Net Income -73.93 M, EPS -3.3641

Aug4

Earning Release(EST)

FY2025 Q2 Earning Release (USD) Net Income -71.13 M, EPS -3.3121

May2

Earning Release(EST)

FY2025 Q1 Earning Release (USD) Net Income -69.3 M, EPS -3.291

Stock List

Top Gainers

Top Decliners

China Concepts

Symbol

Price

%Chg

Change